Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Phys Rev Lett ; 110(2): 021301, 2013 Jan 11.
Article in English | MEDLINE | ID: mdl-23383885

ABSTRACT

The effect of a stochastic background of cosmological perturbations on the luminosity-redshift relation is computed to second order through a recently proposed covariant and gauge-invariant light-cone averaging procedure. The resulting expressions are free from both ultraviolet and infrared divergences, implying that such perturbations cannot mimic a sizable fraction of dark energy. Different averages are estimated and depend on the particular function of the luminosity distance being averaged. The energy flux being minimally affected by perturbations at large z is proposed as the best choice for precision estimates of dark-energy parameters. Nonetheless, its irreducible (stochastic) variance induces statistical errors on Ω(Λ)(z) typically lying in the few-percent range.

5.
Article in English | MEDLINE | ID: mdl-7648282

ABSTRACT

HIV is known to be present in massive amounts in both resting and actively replicating cells in infected individuals. We tested the combination of didanosine and hydroxyurea, known to suppress viral production in vitro in both of these cell types, in a small number of asymptomatic patients. After 3 months of well tolerated treatment, we observed a large reduction of viral load in the peripheral blood of all 12 patients, down to nonquantifiable levels in 7 of 12 as measured by infectious virus titer, and 6 of 12 as measured by plasma HIV-RNA. In this subgroup of 6 patients, whose baseline HIV-RNA was below 14,000 copies/ml, the median increase in CD4+ count after 90 days of treatment was 244 cells/mm3.


Subject(s)
Antiviral Agents/therapeutic use , Didanosine/therapeutic use , HIV Seropositivity/drug therapy , Hydroxyurea/therapeutic use , Adult , CD4 Lymphocyte Count , Drug Therapy, Combination , Drug Tolerance , Female , Humans , Male , Middle Aged , Pilot Projects , RNA, Viral/blood
6.
Cornea ; 12(1): 19-24, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8384543

ABSTRACT

The emergence of cross-resistance to various antiviral drugs was investigated both in vivo and in vitro for herpes simplex virus type 1 (HSV1) resistant to idoxuridine (IUdR 0.24%) obtained by seven successive passages (from P0 to P7) in rabbit keratitis treated by IUdR. The viral population obtained at the seventh IUdR passage (P7) showed an activity of the thymidine kinase (TK) reduced to 5.6% of the parental strain (PO); moreover, most of the clones of P7 showed an altered TK phenotype determined by the [125I]iododeoxycytidine (IDC) procedure. In rabbit keratitis, IUdR-resistant viral population P7 showed cross-resistance to bromovinyl desoxyuridine (BVDU) (0.5%) and to acyclovir (ACV) (3%). Under trifluorothymidine (1%) treatment, P7 showed an intermediate sensitivity. HSV1 at P7 remained sensitive to adenine arabinoside (Ara A) (3%) and to dihydroxy-propoxymethylguanine used at high concentration (3%). The in vitro sensitivity determination to various antiviral drugs was investigated by dye-uptake assay for the initial viral population PO and for HSV1 collected under IUdR treatment at the third (P3) and the seventh (P7) passages. Cross-resistance to TK-dependent drugs, such as IDC, BVDU, and ACV were found at P7. P7 remained sensitive to Ara A and to phosphonoformic acids antiviral drugs known not to be dependent on viral TK.


Subject(s)
Antiviral Agents/therapeutic use , Idoxuridine/therapeutic use , Keratitis, Herpetic/drug therapy , Animals , Drug Resistance, Microbial , Female , Keratitis, Herpetic/microbiology , Microbial Sensitivity Tests , Phenotype , Rabbits , Random Allocation , Simplexvirus/drug effects , Simplexvirus/metabolism , Thymidine Kinase/metabolism
7.
J Med Virol ; 36(1): 1-12, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1315366

ABSTRACT

For the past 2 years, a survey network was established for the screening of acyclovir (ACV)-resistant clinical isolates of herpes simplex virus (HSV). Among 889 strains tested for in vitro ACV sensitivity, 14 HSV-1 and 6 HSV-2 were resistant to ACV concentrations exceeding 3 micrograms/ml. These resistant isolates were most often obtained after prolonged ACV treatment of severely immunocompromised patients. For five patients, the emergence of ACV-resistant virus correlated with treatment failure. In particular, a decrease in the in vitro sensitivity to ACV was observed for eight successive HSV-1 isolates from one immunodeficient patient undergoing therapy. All ACV-resistant isolates were studied for their sensitivity to different antiherpetic compounds and showed various cross-sensitive and -resistant patterns. The examination of viral populations by plaque autoradiography procedures frequently revealed their heterogeneity in terms of thymidine kinase (TK) phenotype and allowed the detection of various proportions of TK-positive (TK+), TK-deficient (TKD), or TK-altered (TKA) viruses. Our data underline the importance of monitoring the emergence of drug-resistant virus during the course of antiviral therapy, and the need for the detection and characterization of TK mutants in clinical specimens. The routine examination of drug sensitivity of HSV isolates provides useful information to clinicians for the management of ACV treatment in the hope of preventing ACV-resistant mutants from becoming predominant in mixed viral populations.


Subject(s)
Acyclovir/pharmacology , Drug Monitoring , Drug Resistance , Herpes Simplex/drug therapy , Simplexvirus/genetics , Antiviral Agents/pharmacology , Genetic Variation , Humans , Microbial Sensitivity Tests , Mutagenesis , Simplexvirus/classification , Simplexvirus/enzymology , Thymidine Kinase/deficiency , Thymidine Kinase/genetics
8.
C R Acad Sci III ; 314(10): 443-9, 1992.
Article in French | MEDLINE | ID: mdl-1325862

ABSTRACT

During 7 serial passages of Herpes Simplex Virus (HSV1) in rabbit cornea treated with idoxuridine (IUdR) (P1 to P7), the emergence of resistance had been obtained from P3. The reversion towards IUdR sensitivity has been investigated from either viral population P3 or P6 by 6 serial passages in rabbit cornea treated by Vaseline (V1 to V6). From viral population P3, the reversion to IUdR sensitivity has been obtained at V4. In contrast, from viral population P6, the IUdR resistance was conserved from V1 to V6. In vitro, on Vero cells, the effective doses 50% (ED50) and 90% (ED90), determined by dye uptake assay and plaque reduction assay, confirmed the reversibility towards IUdR sensitivity obtained from P3 and the stability of IUdR resistance from P6.


Subject(s)
Idoxuridine/pharmacology , Keratitis, Herpetic/drug therapy , Simplexvirus/drug effects , Animals , Dose-Response Relationship, Drug , Drug Resistance, Microbial/physiology , Idoxuridine/therapeutic use , In Vitro Techniques , Placebos , Rabbits
9.
Curr Eye Res ; 10 Suppl: 151-8, 1991.
Article in English | MEDLINE | ID: mdl-1650663

ABSTRACT

The acquisition of drug resistance in vivo was investigated by 7 serial passages (from P0 to P7) of herpes simplex virus (HSV-1) in rabbit cornea treated with either IUdR (idoxuridine), IDC (idoxycytidine), ACV (acyclovir), TFT (trifluridine), or Ara A (adenine arabinoside). Therapeutic failure was acquired gradually: at P3 for IUdR, at P4 for ACV and at P5 for TFT. At P7, viral thymidine kinase (TK) activity was reduced to 5.6% of the parental strain for IUdR, to 7.5% for ACV and to 4.6% for TFT treatment. No signs of clinical unresponsiveness occurred with IDC or Ara A. The in vitro determination of antiviral drug sensitivity performed by the dye-uptake assay on HSV isolates at each passage showed a correlation between the increase in the 50% effective dose (ED50) and the increase of ulcer area grade at each passage under antiviral drug (p less than 0.1). Both IUdR- and TFT-resistant HSV1 developed cross-resistances to TK dependent drugs. However ACV-resistant HSV1 did not show cross-resistance to other antiviral TK dependent drugs. The acquisition of the cross-resistances is discussed, and the practical implications in case of therapeutic failures are suggested.


Subject(s)
Antiviral Agents/therapeutic use , Keratitis, Dendritic/drug therapy , Simplexvirus/drug effects , Animals , Antiviral Agents/administration & dosage , Drug Resistance, Microbial , Female , Lethal Dose 50 , Microbial Sensitivity Tests , Rabbits , Simplexvirus/isolation & purification , Virus Cultivation
10.
J Biol Stand ; 14(3): 201-11, 1986 Jul.
Article in English | MEDLINE | ID: mdl-3020058

ABSTRACT

A rapid and sensitive colorimetric assay has been developed to evaluate the sensitivity of herpes simplex viruses (HSV) to antiviral agents. The chessboard titration of viruses and antiviral drugs and the automatic reading and analysis of the data allows objective and accurate results to be rapidly obtained. Virus sensitivity was expressed as an ED50 value which was the concentration of drug (micrograms/ml) reducing viral cpe by 50%. The ED50 values of antiviral drugs [acetylguanosine (ACV), idoxuridine (IDU), deoxycytidine (IDC) and bromovinyl deoxyuridine] for several HSV reference strains were determined and the method was then applied to clinical specimens. The selection of ACV and IDU resistant mutants was performed on a cloned sensitive HSV 1 ocular strain. We observed cross-resistance between ACV and IDU for the mutants isolated. The resistance to thymidine-kinase-dependent antiviral agents varied in inverse ratio to the thymidine kinase activity induced by HSV strains.


Subject(s)
Antiviral Agents/pharmacology , Colorimetry/methods , Microbial Sensitivity Tests/methods , Simplexvirus/drug effects , Mutation , Simplexvirus/enzymology , Simplexvirus/genetics , Thymidine Kinase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...